Here are four points:
1. The study will examine the safety and efficacy of its allogeneic cell therapy product ALLOB for spinal fusions.
2. In total, 18 patients have been enrolled in the study.
3. The company is extending the trial to assess early onset of bone formation and fusion.
4. The complete set of efficacy results are expected in the second quarter of 2017.
More articles on devices:
Amedica lowers total debt obligations 47% to $12.9M: 5 key notes
Osiris Therapeutics finds better outcomes with Grafix vs. EpiFix — 5 points
CONMED stock “buy” rating reiterated: 3 notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
